Trial Profile
A Pilot, Randomized Study Comparing the Safety, Tolerability and Pharmacokinetics of Combination Therapy (Amantadine, Ribavirin, Oseltamivir) Versus Neuraminidase Inhibitor Monotherapy to Influenza Virus Infected Immunocompromised Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Amantadine/ribavirin (Primary) ; Amantadine; Oseltamivir; Ribavirin; Zanamivir
- Indications Influenza A virus infections
- Focus Adverse reactions
- 19 Jul 2011 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 19 Jul 2011 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 19 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.